Written Question·Department of Health and Social Care·UIN 69242
Drugs: Licensing
Tabled: 21 July 2025
Answered: 1 September 2025
Question
Jim Shannon
Democratic Unionist Party — Strangford
To ask the Secretary of State for Health and Social Care, if he will make an assessment of the potential merits of requiring NHS England to establish an agreement in principle with pharmaceutical companies that commercial flexibility may be granted for a
Answer
Karin SmythIndication-specific pricing can support access to treatments, including for rare conditions, by enabling companies to propose a specific price for smaller indications that would otherwise be commercially unviable under a uniform price.In January 2025, fol...
ⓘ
This is an extract from the Parliament API. Search the full answer on Parliament.uk (UIN 69242) →